Abstract
The antidiuretic effect of two chemically related drugs, clofibrate and halofenate, was tested in a patient with pitressin-sensitive diabetes insipidus. The conventional daily dosage of 2 g clofibrate failed to control the symptoms of this patient; in order to obtain an adequate response the dosage had to be increased to 4 g daily.
Halofenate at a dosage of 2 g daily, an amount equivalent in hypolipidemic activity to 4 g per day of clofibrate, significantly reduced water intake and output, while urinary osmolarity was markedly increased.
It is concluded that (1) the antidiuretic effect of clofibrate may be dose-related, and that (2) halofenate also possesses some antidiuretic activity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERRY C., MOXHAM A., SMITH E., KELLIE A. E., NABARRO J. D. THE EFFECTS OF ATROMID ON THE METABOLISM OF ADRENAL STEROIDS AND ON PLASMA LIPID FRACTIONS. J Atheroscler Res. 1963 Sep-Dec;3:380–395. doi: 10.1016/s0368-1319(63)80019-8. [DOI] [PubMed] [Google Scholar]
- Chrétien M., Lewis W. Effet antidiurétique du clofibrate dans le diabète insipide. Union Med Can. 1971 Oct;100(10):1952–1954. [PubMed] [Google Scholar]
- Danowski T. S., Cohn R. E., Limaye N. R., Novak J. F., Saul R., Sunder J. H., Moses C. Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus. Clin Pharmacol Ther. 1965 Nov-Dec;6(6):716–730. doi: 10.1002/cpt196566716. [DOI] [PubMed] [Google Scholar]
- GREEN K. G., INMAN W. H., THORP J. M. MULTICENTRE TRIAL IN THE UNITED KINGDOM AND IRELAND OF A MIXTURE OF ETHYL CHLOROPHENOXYISOBUTYRATE AND ANDROSTERONE (ATROMID). A PRELIMINARY REPORT. J Atheroscler Res. 1963 Sep-Dec;3:593–616. doi: 10.1016/s0368-1319(63)80043-5. [DOI] [PubMed] [Google Scholar]
- HELLMAN L., ZUMOFF B., KESSLER G., KARA E., RUBIN I. L., ROSENFELD R. S. REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE. Ann Intern Med. 1963 Oct;59:477–494. doi: 10.7326/0003-4819-59-4-477. [DOI] [PubMed] [Google Scholar]
- HOWARD R. P., ALAUPOVIC P., BRUSCO O. J., FURMAN R. H. EFFECTS OF ETHYL CHLOROPHENOXYISOBUTYRATE, ALONE OR WITH ANDROSTERONE (ATROMID) ON SERUM LIPIDS, LIPOPROTEINS AND RELATED METABOLIC PARAMETERS IN NORMAL AND HYPERLIPIDEMIC SUBJECTS. J Atheroscler Res. 1963 Sep-Dec;3:482–499. doi: 10.1016/s0368-1319(63)80028-9. [DOI] [PubMed] [Google Scholar]
- OLIVER M. F. Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet. 1962 Jun 23;1(7243):1321–1323. doi: 10.1016/s0140-6736(62)92422-4. [DOI] [PubMed] [Google Scholar]
- Uhlich E., Loeschke K., Eigler J., Halbach R. Clofibrat bei Diabetes insipidus. Klin Wochenschr. 1971 Apr 1;49(7):436–437. doi: 10.1007/BF01485002. [DOI] [PubMed] [Google Scholar]
- de Gennes J. L., Bertrand C., Bigorie B., Truffert J. Etudes préliminaires de l'action antidiurétique du clofibrate (ou atromid S) dans le diabète insipide pitressosensible. Ann Endocrinol (Paris) 1970 Mar-Apr;31(2):300–308. [PubMed] [Google Scholar]